Takeda commences new phase of corporate restructuring

Takeda is moving to further support its future growth initiatives through the commencement of a new phase of its transformation plans.

The company has commenced its 2011-2013 Mid-Range Plan, replacing its previous 2010-12 initiative, which will aim to restore its financial growth performance and improve its global pharmaceutical leadership positioning.

Among the objectives of the plan are investments of resources in core areas such as metabolic disease, oncology and immunology, as well as enhancing the competitiveness of its pipeline and boosting its research productivity.

Other key priorities include increasing the company's strategic investment activity, expanding its global reach and improving the expertise and diversity of the workforce.

The company noted that its transformation activities in 2010 brought success with the creation of the Shonan Research Center, the new focal point of its global research network, as well as the launch of several new products.

Earlier this month, it was announced that Takeda is making an investment in Fate Therapeutics, a deal which expands its presence in the regenerative medicine field.